Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its twelfth annual Drugs to Watch report, highlighting eleven therapies poised to redefine the future of healthcare. These innovations, addressing critical challenges in areas such as obesity, oncology, and gene therapy, are forecast to achieve blockbuster sales by 2030 or dramatically improve patient outcomes on a global scale. The report, powered by insights from the Clarivate Cortellis intelligence suite of products, offers an in-depth analysis of the chronic disease market in Mainland China, spotlighting five therapies expected to exceed $1 billion in annual sales over the next five years or deliver transformative outcomes for patients.